These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9865302)

  • 81. Mycophenolate mofetil decreases the risk for chronic renal allograft failure.
    Meier-Kriesche H; Ojo AO; Arndorfer JA; Magee JC; Cibrik DM; Leichtman AB; Campbell DA; Kaplan B
    Transplant Proc; 2001; 33(1-2):1005-6. PubMed ID: 11267165
    [No Abstract]   [Full Text] [Related]  

  • 82. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The effect of different immunosuppression on the outcome of pediatric renal transplants.
    García Meseguer C; Alonso A; Vanegas JJ; Martinez Débora MJ; Navarro M
    Transplant Proc; 1999 Sep; 31(6):2280. PubMed ID: 10500577
    [No Abstract]   [Full Text] [Related]  

  • 84. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression.
    Tanabe K; Tokumoto T; Ishikawa N; Kanematsu A; Oshima T; Harano M; Inui M; Yagisawa T; Nakajima I; Fuchinoue S; Takahashi K; Toma H
    Transplant Proc; 1999 Nov; 31(7):2877-9. PubMed ID: 10578323
    [No Abstract]   [Full Text] [Related]  

  • 85. beta-herpesvirus activation after kidney transplantation with mycophenolate mofetil-based maintenance immunosuppression.
    Folkmane I; Chapenko S; Amerika D; Bicans J; Murovska M; Rosentals R
    Transplant Proc; 2001 May; 33(3):2384-5. PubMed ID: 11377569
    [No Abstract]   [Full Text] [Related]  

  • 86. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
    Yu L; Wang Y; Fu SJ; Cheng XJ
    Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
    [No Abstract]   [Full Text] [Related]  

  • 87. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The replacement of azathioprine by mycophenolate mofetil in pediatric patients with specific risks in renal transplantation.
    Anguita A; Repetto HA; Rodriguez-Rilo L; Vazquez LA; Iturzaeta A; Morrone G; Deheza R; Maldonado L; Goldberg JL
    Transplant Proc; 1999 Sep; 31(6):2279. PubMed ID: 10500576
    [No Abstract]   [Full Text] [Related]  

  • 89. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients.
    Lietz K; John R; Schuster M; Ankersmit J; Burke E; Suciu-Foca N; Edwards N; Mancini D; Itescu S
    Transplant Proc; 2002 Aug; 34(5):1828-9. PubMed ID: 12176593
    [No Abstract]   [Full Text] [Related]  

  • 90. Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft survival.
    Kumar AM; Fa K; Vankawala R; Vora M; Kode RK; Pankewycz OG; Lattavi MR; Fyfe B; Damask AM; Ferry E; Stabler S; Tomeny MB; Phillips K; Lingaraju R; Kumar MS
    Transplant Proc; 2001; 33(7-8):3195-6. PubMed ID: 11750370
    [No Abstract]   [Full Text] [Related]  

  • 91. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
    Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
    Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
    Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
    Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
    [TBL] [Abstract][Full Text] [Related]  

  • 94. One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study.
    Seebacher G; Weigel G; Griesmacher A; Mallinger R; Zuckermann A; Grimm M; Laufer G
    Transplant Proc; 1999 Dec; 31(8):3291-3. PubMed ID: 10616480
    [No Abstract]   [Full Text] [Related]  

  • 95. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation.
    Süleymanlar G; Tuncer M; Sarikaya M; Ersoy F; Aktan S; Yakupoğlu G; Karpuzoğlu T
    Transplant Proc; 2001 Aug; 33(5):2780-1. PubMed ID: 11498158
    [No Abstract]   [Full Text] [Related]  

  • 96. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine.
    Izbicki G; Shitrit D; Aravot D; Sulkes J; Saute M; Sahar G; Kramer MR
    Transplant Proc; 2002 Dec; 34(8):3258-9. PubMed ID: 12493439
    [No Abstract]   [Full Text] [Related]  

  • 97. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.
    Chavers BM; Chang YC; Gillingham KJ; Matas A
    Transplantation; 2009 Jul; 88(2):237-41. PubMed ID: 19623020
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation.
    Land W
    Transplant Proc; 1999 Dec; 31(8A):27S-32S. PubMed ID: 10616558
    [No Abstract]   [Full Text] [Related]  

  • 99. Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients.
    Bravo Soto JA; Esteban de la Rosa RJ; Luna del Castillo JD; Cerezo Morales S; García Olivares E; Osuna Ortega A; Asensio Peinado C
    Transplant Proc; 2003 Jun; 35(4):1355-9. PubMed ID: 12826158
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mycophenolate mofetil in renal transplantation: five years experience.
    Tuncer M; Gürkan A; Erdoğan O; Demirbaş A; Süleymanlar G; Ersoy FF; Akaydin M; Yakupoğlu G
    Transplant Proc; 2002 Sep; 34(6):2087-8. PubMed ID: 12270324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.